HCSCI Completes RMB 200 Million Series B Financing to Advance Intelligent Solutions in Life Science

VCBeat (WeChat ID: vcbeat) has learned that Chengdu Hanchenguangyi Technology Co., Ltd. (“Hanchenguangyi”) previously completed a RMB 200 million Series B financing round. This round introduced new investors Legend Capital, LYFE Capital, and Innovation Works, while existing shareholders Boyuan Capital, Northern Light Venture Capital, and Yunzhi Capital continued to increase their investments. The additional capital from this round will support Hanchenguangyi in expanding product R&D, building out more product pipelines, strengthening team development, and advancing market expansion.

Hanchenguangyi has completed four rounds of financing to date, with the details of each round as follows:

Chengdu Hanchenguangyi Technology Co., Ltd. commenced operations in April 2016. Guided by its corporate mission to “empower life sciences and achieve the extraordinary through simplicity,” the company focuses on the research and development of intelligent solutions for the life sciences sector, striving to become the most trusted partner for global life science customers. In the 21st century, humanity has accelerated its exploration in the field of life sciences, with numerous niche segments experiencing unprecedented rapid growth. Technological advancement is inseparable from the support of diverse research tools. To date, Chengdu Hanchenguangyi has successfully developed multiple intelligent life science tool platforms, with a product pipeline covering application areas such as in vitro diagnostics, modern agriculture, and scientific research. These innovations significantly reduce cumbersome operational tasks for life science professionals, creating value for every partner.

In the field of in vitro diagnostics (IVD), molecular diagnostics is gradually becoming one of the most critical diagnostic technologies due to its outstanding advantages in reaction sensitivity and detection accuracy. However, compared with traditional biochemical and immunological methods, its experimental procedures are cumbersome and complex. The surge in testing demand driven by the COVID-19 pandemic has created substantial market demand for high-throughput, integrated testing systems. Chengdu Hanchenguangyi Technology Co., Ltd. has developed an integrated qPCR molecular diagnostic platform that enables high-throughput “sample-in, result-out” processing with no manual intervention throughout the entire testing workflow, thereby further promoting the application of molecular diagnostic technologies in pathogen detection. In terms of sequencing technology applications, the company has also developed a high-throughput automated integrated platform for next-generation sequencing (NGS) sample preparation. This platform provides an end-to-end solution ranging from nucleic acid extraction to library preparation, significantly enhancing equipment integration and automation. It facilitates pre-sequencing sample preparation across a broader range of scenarios, helping to drive more extensive and timely adoption of gene sequencing technologies.

In the field of modern agriculture, China has achieved certain results at an internationally advanced level. However, key upstream equipment remains monopolized by foreign industry giants, leading to high product prices and supply chain risks. The 2020 Central Economic Work Conference pointed out the need to address issues related to seeds and arable land, conduct breakthroughs in "chokehold" technologies for germplasm resources, and strive to win a turnaround battle in the seed industry. Chengdu Hanchenguangyi Technology Co., Ltd. has independently developed multiple high-throughput testing equipment platforms and supporting consumables/reagents. These can be used in areas including molecular-assisted breeding, livestock disease detection, identification of animal and plant varieties and strains, conservation and utilization of germplasm resources, and GMO detection. To date, the company has completed installations for dozens of leading seed companies, large research institutions, and third-party testing agencies, with cumulative tests reaching tens of millions.

In the field of scientific research, Chengdu Hanchenguangyi Technology Co., Ltd. deeply aligns with customer needs to develop integrated smart laboratory solutions. The precision, high throughput, reproducibility, safety, and cleanliness required for the rapid development of life science laboratories pose significant challenges to manual operations. Smart laboratories, through the comprehensive application of robotics, microfluidics, automation, artificial intelligence, and other technologies, help transform the traditional laboratory landscape characterized by cumbersome processes, low efficiency, and inconvenient management. In a smart laboratory environment, experimental assembly lines connected by robots organically integrate various instruments and equipment through flexible expansion and modular configuration, forming an efficient, accurate, and seamlessly collaborative intelligent system. Under the coordination and scheduling of laboratory automation software, laboratories can conduct high-throughput, high-quality experiments in an unattended manner.

Exploration and development across the various subfields of life sciences are just beginning, and the anticipated surge in the adoption of intelligent, comprehensive solutions is poised to create a vast blue-ocean market in the future. Chengdu Hanchenguangyi Technology Co., Ltd. will deepen its commitment to the life sciences sector, continuously expand its product pipeline, strengthen its presence in the domestic market while expanding into international markets, and provide intelligent, end-to-end solutions to customers across diverse technical platforms and application areas within the various subsectors of the global life sciences industry, thereby consistently delivering value to its clients.

Chengdu Tianfu International Bio-town, Headquarters of Hanchenguangyi

Zhou Quan, Managing Director at Legend Capital, stated: “The IVD molecular diagnostics sector is experiencing robust growth, and automation represents an irreversible trend. Nevertheless, China remains heavily reliant on manual operations, a vulnerability that highlighted critical pain points in testing efficiency and resource consumption during the COVID-19 pandemic. The team at Chengdu Hanchenguangyi Technology Co., Ltd. possesses independent R&D and mass-production capabilities across all core modules of the molecular diagnostics workflow, along with a profound understanding of clinical requirements. Accordingly, they have launched a series of fully automated, clinical-grade molecular diagnostic products. We are honored to partner with the company and look forward to its contributions—under the leadership of Dr. Zhang Han—to advancing industries such as molecular diagnostics and agricultural breeding, achieving extraordinary results through relentless effort!”

LYFE Capital (Zhouling Capital) believes that since its inception, Hanchenguangyi has consistently represented the most advanced direction in fully automated intelligent solutions for life sciences. It is a technology-driven company grounded in independent R&D and committed to continuous innovation. Dr. Zhang Han, the founder, has built a team of senior engineers characterized by exceptional craftsmanship around the company’s core technology platform. By leveraging microfluidics and automation technologies, the company continuously addresses the most urgent needs in clinical practice, scientific research, agriculture, and the broader life sciences sector. As a long-term partner, LYFE Capital (Zhouling Capital) will continue to support the company’s strategy of leveraging innovative technologies while targeting global market expansion. Furthermore, LYFE Capital (Zhouling Capital) will empower the company through resources within its global ecosystem, jointly building an internationally recognized platform enterprise.

Dr. Shi Chengxi, Investment Director at Innovation Works, stated: “The transformation brought about by automation and intelligence is currently”Fundamentally transforming the life sciences industry and enhancing overall industrial efficiency. Chengdu Hanchenguangyi Technology Co., Ltd. is an innovative driver providing intelligent automation products and solutions for the life sciences sector. It has developed a range of automated testing equipment and smart laboratory solutions tailored to diverse scenarios, including in vitro diagnostics (IVD), modern agriculture, and scientific research. Hospital clients can significantly reduce personnel and space requirements while accelerating clinical testing speeds by using the company’s automated instruments. Agricultural clients leveraging the company’s high-throughput platforms can achieve a hundredfold increase in testing throughput and reduce costs by over 90%, delivering substantial value in cost reduction and efficiency improvement. The company’s founding team is ambitious, adhering to long-termist values and maintaining an international perspective. Innovation Works is optimistic about Hanchenguangyi’s prospects and looks forward to supporting it over the long term in becoming an industry leader, driving the automation and intelligent upgrading of the global life sciences field with Chinese innovation.